Mevion Medical Systems is a technology company.
Mevion Medical Systems has raised $85.0M across 3 funding rounds.
Mevion Medical Systems has raised $85.0M in total across 3 funding rounds.
Mevion Medical Systems has raised $85.0M in total across 3 funding rounds.
Mevion Medical Systems's investors include Acorn Bioventures, Flagship Ventures, Polaris Partners.
Mevion Medical Systems is a radiation therapy company specializing in compact proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, it develops the MEVION S250 Series, including models like the S250-FIT, which fits into existing LINAC vaults and offers 98% uptime, serving cancer centers, clinicians, and patients worldwide.[1][2][3][4]
The company solves the problem of inaccessible proton therapy by providing smaller, lower-cost systems compared to traditional setups, enabling more NCI-designated cancer centers to adopt it. It demonstrates strong growth momentum through recent FDA clearances (e.g., S250-FIT in 2025), partnerships like Carilion Clinic and Loma Linda University Health, and installations such as BayCare Cancer Institute, with total funding exceeding $595 million.[3][4][5]
Mevion Medical Systems, originally named Still River Systems, Inc., was founded in 2004 in Massachusetts to pioneer compact proton therapy solutions, addressing the limitations of bulky, expensive traditional systems.[1][4] The idea emerged from a need to make proton therapy—a precise radiation method that targets tumors while sparing healthy tissue—more practical for widespread hospital use.[2][3]
Early traction came from inventing the compact proton therapy model, evolving into the MEVION S250 Series. Pivotal moments include FDA clearances for advanced systems and deliveries to centers like Mercy Hospital (2021) and Kansas City Proton Institute (2023), building toward recent 2025 milestones like the S250-FIT approval and new site announcements.[3][5]
Mevion rides the trend of precision oncology, where proton therapy gains traction for treating complex cancers like pediatric and brain tumors due to its superior dose control over X-ray radiation.[2][3] Timing aligns with rising demand for outpatient cancer care and cost-effective medtech, fueled by FDA approvals and hospital expansions amid an aging population and cancer prevalence.[3][5]
Market forces favoring Mevion include compact tech enabling retrofits in existing facilities, lowering barriers in a $10B+ radiation therapy market, and partnerships with pioneers like Loma Linda (first U.S. hospital-based proton center).[3] It influences the ecosystem by accelerating proton adoption—over 50 global centers use its systems—driving industry standards for accessibility and spurring competitors toward miniaturization.[2][4]
Mevion is poised for expansion with 2025 wins like S250-FIT clearance and new U.S. sites (e.g., Central Massachusetts, Southwest Virginia), potentially scaling installations amid proton therapy's 10-15% annual growth.[3][4][5] Trends like AI-driven planning, FLASH therapy, and global demand (e.g., Mevion China orders) will shape its path, enhancing precision and speed.[3][5]
Its influence may evolve by dominating compact systems, enabling more centers worldwide and pressuring incumbents on cost, ultimately fulfilling proton therapy's promise as Mevion's compact innovation continues transforming cancer care from niche to standard.[2][3]
Mevion Medical Systems has raised $85.0M across 3 funding rounds. Most recently, it raised $45.0M Venture Round in January 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2012 | $45.0M Venture Round | Acorn Bioventures, Flagship Ventures, Polaris Partners | |
| Dec 1, 2008 | $33.0M Venture Round | Acorn Bioventures, Flagship Ventures, Polaris Partners | |
| Oct 1, 2007 | $7.0M Series C | Acorn Bioventures, Flagship Ventures, Polaris Partners |